Last reviewed · How we verify
Intravenous stem cell transplantation
Intravenous stem cell transplantation is a Small molecule drug developed by Southern Medical University, China. It is currently in Phase 1 development.
At a glance
| Generic name | Intravenous stem cell transplantation |
|---|---|
| Sponsor | Southern Medical University, China |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Nausea
- Diarrhoea
- Infection
- Pneumonia
- Graft versus host disease
- Hypertension
- Pyrexia
- Rash
- Vomiting
- Headache
- Mucositis
- Fatigue
Key clinical trials
- Safety and Efficacy Study of Transplantation of Autologous CD34+ Cells Transduced With the G2ARTE Lentiviral Vector Expressing the DCLRE1C cDNA in Artemis (DCLRE1C) Deficient Severe Combined Immunodeficiency Patients (ARTEGENE) (PHASE1, PHASE2)
- A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma. (PHASE1, PHASE2)
- Efficacy METAZYM for the Treatment Metachromatic Leukodystrophy Treated With Hematopoietic Stem Cell Transplantation (PHASE2)
- HIV Antigen-specific T-cells Targeting Conserved Epitopes (HST-NEETs) BMTCTN1903 (PHASE2)
- Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older (PHASE2)
- Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease (PHASE1, PHASE2)
- A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma (PHASE2)
- Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravenous stem cell transplantation CI brief — competitive landscape report
- Intravenous stem cell transplantation updates RSS · CI watch RSS
- Southern Medical University, China portfolio CI
Frequently asked questions about Intravenous stem cell transplantation
What is Intravenous stem cell transplantation?
Intravenous stem cell transplantation is a Small molecule drug developed by Southern Medical University, China.
Who makes Intravenous stem cell transplantation?
Intravenous stem cell transplantation is developed by Southern Medical University, China (see full Southern Medical University, China pipeline at /company/southern-medical-university-china).
What development phase is Intravenous stem cell transplantation in?
Intravenous stem cell transplantation is in Phase 1.
What are the side effects of Intravenous stem cell transplantation?
Common side effects of Intravenous stem cell transplantation include Nausea, Diarrhoea, Infection, Pneumonia, Graft versus host disease, Hypertension.